Loading
A phase 1/2 trial of EB-DUO-CAR-NK-CEA/GCC in colorectal cancer, run by Beijing Biotech, now recruiting.
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer is a phase 1/2 interventional study registered as NCT07589517 by Beijing Biotech, with 48 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUO-CAR-NK-CEA/GCC and Lymphodepletion.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CEACAM5, HER2-amplified colorectal cancer, HER2, Colorectal cancer and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares CEACAM5, Colorectal cancer and the tag pipeline.
Shares CEACAM5, Colorectal cancer and the tag pipeline.
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/